Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Description
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.16 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.86 | |||||
| Beneish M-Score | -1.6 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -69.7 | |||||
| 3-Year EBITDA Growth Rate | 16.2 | |||||
| 3-Year EPS without NRI Growth Rate | 17.9 | |||||
| 3-Year FCF Growth Rate | 9.9 | |||||
| 3-Year Book Growth Rate | 23.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 426.63 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.63 | |||||
| 9-Day RSI | 41.38 | |||||
| 14-Day RSI | 42.11 | |||||
| 6-1 Month Momentum % | 57.81 | |||||
| 12-1 Month Momentum % | -66.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.66 | |||||
| Quick Ratio | 5.66 | |||||
| Cash Ratio | 5.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.4 | |||||
| Shareholder Yield % | 1.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10972.94 | |||||
| Net Margin % | -5142.56 | |||||
| FCF Margin % | -9186.36 | |||||
| ROE % | -37.57 | |||||
| ROA % | -26.15 | |||||
| ROIC % | -185.86 | |||||
| ROC (Joel Greenblatt) % | -484.6 | |||||
| ROCE % | -61.19 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 121.28 | |||||
| PB Ratio | 0.9 | |||||
| Price-to-Tangible-Book | 0.87 | |||||
| EV-to-EBIT | -0.31 | |||||
| EV-to-Forward-EBIT | -1.22 | |||||
| EV-to-EBITDA | -0.31 | |||||
| EV-to-Revenue | 33.63 | |||||
| EV-to-Forward-Revenue | 28.15 | |||||
| EV-to-FCF | -0.37 | |||||
| Price-to-Net-Current-Asset-Value | 1.65 | |||||
| Price-to-Net-Cash | 1.82 | |||||
| Earnings Yield (Greenblatt) % | -322.58 | |||||
| FCF Yield % | -84.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ovid Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.579 | ||
| EPS (TTM) (€) | -0.427 | ||
| Beta | 0.75 | ||
| Volatility % | 95.67 | ||
| 14-Day RSI | 42.11 | ||
| 14-Day ATR (€) | 0.03131 | ||
| 20-Day SMA (€) | 0.96275 | ||
| 12-1 Month Momentum % | -66.11 | ||
| 52-Week Range (€) | 0.625 - 3.62 | ||
| Shares Outstanding (Mil) | 71.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ovid Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ovid Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ovid Therapeutics Inc Frequently Asked Questions
What is Ovid Therapeutics Inc(STU:1OT)'s stock price today?
The current price of STU:1OT is €0.91. The 52 week high of STU:1OT is €3.62 and 52 week low is €0.63.
When is next earnings date of Ovid Therapeutics Inc(STU:1OT)?
The next earnings date of Ovid Therapeutics Inc(STU:1OT) is 2025-03-07 Est..
Does Ovid Therapeutics Inc(STU:1OT) pay dividends? If so, how much?
Ovid Therapeutics Inc(STU:1OT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers